研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

基因突变病例对照研究中实验结果与期望不符

2021-08-11 MedSci原创 MedSci原创

关注

基因突变病例对照研究-19.

 

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1756178, encodeId=4b791e56178e8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Oct 09 10:50:29 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984147, encodeId=6e87198414ee2, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Nov 08 09:50:29 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775574, encodeId=15f81e75574ae, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Jun 24 21:50:29 CST 2022, time=2022-06-24, status=1, ipAttribution=)]
    2021-10-09 xugc

    #病例对照#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1756178, encodeId=4b791e56178e8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Oct 09 10:50:29 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984147, encodeId=6e87198414ee2, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Nov 08 09:50:29 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775574, encodeId=15f81e75574ae, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Jun 24 21:50:29 CST 2022, time=2022-06-24, status=1, ipAttribution=)]
    2021-11-08 fengyi812

    #病例对照研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1756178, encodeId=4b791e56178e8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Sat Oct 09 10:50:29 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984147, encodeId=6e87198414ee2, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Nov 08 09:50:29 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775574, encodeId=15f81e75574ae, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Jun 24 21:50:29 CST 2022, time=2022-06-24, status=1, ipAttribution=)]
    2022-06-24 amyloid

    #对照#

    0